CSL

Contact
cslbehring.ch
+41-31-344-4444

CSL Behring AG

Wankdorfstrasse 10
3000 Bern
Switzerland
+41-31-344-4444
cslbehring.ch
Contact
Profile Products News
Contact

About CSL

CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself.

Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do. Whether we are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our customers’ needs.

Read more about CSL
Facts about CSL
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of CSL

Product portfolio

Show all

News about CSL

CSL

29-Oct-2014 | business & finance

Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million

Novartis announced it has entered into a definitive agreement to divest its influenza vaccines business to CSL Limited (CSL) for an agreed price of USD 275 ...

Read news
CSL

25-Jan-2013 | research and development

Albumin preserves kidney function and improves survival in abdominal infection of liver disease

Treatment with albumin reduces renal impairment and mortality in cirrhotic patients with spontaneous bacterial peritonitis (SBP), one of the most common ...

Read news
CSL

04-May-2012 | research and development

CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema

Phase I/II study to establish safety and clinical pharmacology with various doses of subcutaneous formulation of human C1-esterase inhibitor

Read news
CSL

28-Mar-2012 | research and development

First Patient Enrolled in CSL Behring PATH Trial to Evaluate Immune Globulin Subcutaneous (Human) 20% Liquid, Hizentra, in the Treatment of CIDP

CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, ...

Read news
CSL

19-Mar-2012 | research and development

CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery

CSL Behring announced that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of ...

Read news
CSL

01-Jun-2011 | research and development

CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment

CSL Behring announced that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion ...

Read news
CSL

11-Mar-2008 | research and development

CSL Behring stellt BLA-Zulassungsantrag für C1-Esterase-Inhibitor zur Behandlung des hereditären Angioödems

Zulassungsentscheidende Studie der Phase II/III zeigt, dass C1-INH bei der Behandlung akuter HAE-Attacken wirksam ist

Read news
CSL

04-Mar-2008 | research and development

Intercell: Licensure application for Japanese Encephalitis vaccine submitted to Therapeutic Goods Administration in Australia

Intercell AG announced the submission of application to register Intercells investigational Japanese Encephalitis vaccine in Australia to the Therapeutic ...

Read news
Show more news about CSL

Here you will find CSL Behring AG